Amylyx Pharmaceuticals, Inc. Balance Sheet
AMLX / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
Amylyx Pharmaceuticals, Inc. had $333M in total assets and $305M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $226.7M | $77.4M | $170.2M | $62.5M | $50.2M |
| Accounts Receivable | - | $447.0K | $40.0M | $15.3M | - |
| Inventory | - | - | $38.3M | $9.8M | - |
| Current Assets | $323.7M | $189.4M | $464.7M | $382.1M | $105.0M |
| PP&E (Net) | $310.0K | $961.0K | $2.7M | $2.6M | $474.0K |
| Total Assets | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M |
| Current Liabilities | $22.7M | $28.4M | $82.0M | $46.6M | $17.4M |
| Shareholders' Equity | $305.3M | $164.8M | $433.4M | $340.6M | -$151.2M |